Oppenheimer & Co. Inc. Sells 104 Shares of Seagen Inc. (NASDAQ:SGEN)

Oppenheimer & Co. Inc. cut its holdings in Seagen Inc. (NASDAQ:SGENFree Report) by 1.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,536 shares of the biotechnology company’s stock after selling 104 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Seagen were worth $1,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Baird Financial Group Inc. boosted its position in shares of Seagen by 4.3% in the 2nd quarter. Baird Financial Group Inc. now owns 25,959 shares of the biotechnology company’s stock worth $4,996,000 after purchasing an additional 1,059 shares in the last quarter. Handelsbanken Fonder AB boosted its position in shares of Seagen by 15.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 61,264 shares of the biotechnology company’s stock worth $11,791,000 after purchasing an additional 8,149 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Seagen by 5.5% in the 2nd quarter. Arizona State Retirement System now owns 40,114 shares of the biotechnology company’s stock worth $7,720,000 after purchasing an additional 2,094 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of Seagen by 6.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,199 shares of the biotechnology company’s stock worth $1,386,000 after purchasing an additional 409 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Seagen by 7.6% in the 2nd quarter. BlackRock Inc. now owns 12,041,819 shares of the biotechnology company’s stock worth $2,317,568,000 after purchasing an additional 850,697 shares in the last quarter. 84.26% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Truist Financial restated a “hold” rating and issued a $229.00 price objective on shares of Seagen in a report on Wednesday, October 18th. TheStreet lowered shares of Seagen from a “c-” rating to a “d+” rating in a report on Friday, November 3rd. Finally, StockNews.com assumed coverage on shares of Seagen in a research note on Thursday, February 1st. They set a “hold” rating for the company. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $197.69.

Read Our Latest Analysis on Seagen

Insider Transactions at Seagen

In other news, CEO David R. Epstein sold 10,620 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $213.01, for a total transaction of $2,262,166.20. Following the completion of the transaction, the chief executive officer now directly owns 136,598 shares in the company, valued at approximately $29,096,739.98. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO David R. Epstein sold 10,620 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $213.01, for a total transaction of $2,262,166.20. Following the sale, the chief executive officer now directly owns 136,598 shares of the company’s stock, valued at approximately $29,096,739.98. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Vaughn B. Himes sold 8,785 shares of the business’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $213.32, for a total transaction of $1,874,016.20. Following the completion of the transaction, the insider now owns 42,574 shares of the company’s stock, valued at approximately $9,081,885.68. The disclosure for this sale can be found here. Company insiders own 25.90% of the company’s stock.

Seagen Price Performance

Shares of NASDAQ:SGEN opened at $228.74 on Wednesday. The business has a fifty day moving average of $226.43 and a two-hundred day moving average of $213.93. The stock has a market cap of $42.93 billion, a P/E ratio of -57.04 and a beta of 0.32. Seagen Inc. has a 52-week low of $123.77 and a 52-week high of $228.96.

Seagen Profile

(Free Report)

Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

Read More

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seagen Inc. (NASDAQ:SGENFree Report).

Institutional Ownership by Quarter for Seagen (NASDAQ:SGEN)

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.